A pegylated IL-2, NKTR-214, which is a pro-drug and has the preferential release of the active IL-2 in the tumor microenvironment, has an excellent preclinical activity [76] and is now being tested in combination with ICIs for multiple malignancies in multiple settings. This evidence concerns the gene IL2 and neoplasm.